ASIA-PACIFIC OPIOID INDUCED CONSTIPATION DRUG MARKET FORECAST 2017-2025
KEY FINDINGS
The Asia-Pacific Opioid Constipation Drug market is estimated to grow at a CAGR of 5.07% during the forecast period of 2017-2025. The market worth is expected to increase from $233 million in 2016 and reach $361.88 million by 2025. The ease in the availability of new and improved drugs and the growing geriatric population are currently driving the Asian Market.
MARKET INSIGHTS
The Asian market can be classified on the basis of drug type and prescription type. The drug type is further classified into naloxegol, lubiprostone, and methyl naltrexone bromide and some pipeline drugs such as naldemedine, alvimopan, dolcanatide and elobixibat. The prescription type is classified into generic and branded prescribed drugs and over the counter drugs. A large number of considerations while using opioids is a major challenge currently faced by the market.
COMPETITIVE INSIGHTS
Some of the major players in the market are
The Asia-Pacific Opioid Constipation Drug market is estimated to grow at a CAGR of 5.07% during the forecast period of 2017-2025. The market worth is expected to increase from $233 million in 2016 and reach $361.88 million by 2025. The ease in the availability of new and improved drugs and the growing geriatric population are currently driving the Asian Market.
MARKET INSIGHTS
The Asian market can be classified on the basis of drug type and prescription type. The drug type is further classified into naloxegol, lubiprostone, and methyl naltrexone bromide and some pipeline drugs such as naldemedine, alvimopan, dolcanatide and elobixibat. The prescription type is classified into generic and branded prescribed drugs and over the counter drugs. A large number of considerations while using opioids is a major challenge currently faced by the market.
COMPETITIVE INSIGHTS
Some of the major players in the market are
- Daiichi Sankyo Co Ltd
- Pfizer
- Shionogi & Co., Ltd.
- Allergan Plc
- Nektar Therapeutics
- Mundipharma International Limited
- Ono Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Cosmo Pharmaceuticals Sa
- Daewoong Pharmaceutical Co
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. . TOP DOWN APPROACH
2.3. BOTTOM UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
4.5. MARKET DRIVERS
4.5.1. RISING USE OF OPIOID
4.5.2. INCREASING GERIATRIC POPULATION
4.5.3. EASY AVAILABILITY OF IMPROVED AND EFFECTIVE OIC DRUGS
4.6. RESTRAINTS
4.6.1. RESEARCH ON PAIN AND NEXT GENERATION ANALGESICS
4.6.2. SIDE EFFECTS OF OIC DRUGS
4.6.3. UNAWARENESS AND IGNORANCE AMONG PATIENTS
4.7. OPPORTUNITY
4.7.1. RISING DEMAND FOR OIC DRUGS FROM APAC MARKET
4.7.2. INCREASING USE OF OPIOIDS
4.8. CHALLENGES
4.8.1. LARGE NUMBER OF CONSIDERATIONS WHILE USING OPIOIDS
5. ASIA PACIFIC OIC DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)
5.1. OVERVIEW
5.1.1. METHYL NALTREXONE BROMIDE
5.1.2. LUBIPROSTONE
5.1.3. NALOXEGOL
5.2. PIPELINE DRUG ANALYSIS: PHASE 3: NALDEMEDINE (YEAR OF LAUNCH TO 2022 $ MILLION)
5.3. PIPELINE DRUG ANALYSIS: PHASE 2: ALVIMOPAN, DOLCANATIDE (QUALITATIVE INFORMATION)
5.4. PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH TO 2022 $ MILLION)
6. ASIA PACIFIC CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
6.1. PRESCRIBED DRUGS
6.1.1. BRANDED
6.1.2. GENERIC
6.2. OVER THE COUNTER DRUGS
7. KEY ANALYTICS
7.1. PORTERS FIVE FORCE MODEL
7.1.1. INTENSITY OF COMPETITIVE RIVALRYOMPETITION AMONG THE
7.1.2. BARGAINING POWER OF SUPPLIERS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. THREAT OF SUBSTITUTE PRODUCTS
7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX
8. ASIA PACIFIC OIC DRUGS MARKET BY COUNTRIES 2017-2025 ($ MILLION)
8.1. CHINA
8.2. JAPAN
8.3. REST OF ASIA PACIFIC
9. COMPANY PROFILE
9.1. IRONWOOD PHARMACEUTICALS INC
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC MOVES
9.1.4. SCOT ANALYSIS
9.2. DAIICHI SANKYO CO LTD
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. STRATEGIC MOVES
9.2.4. SCOT ANALYSIS
9.3. PFIZER
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. STRATEGIC MOVES
9.3.4. SCOT ANALYSIS
9.4. PROGENICS PHARMACEUTICALS INC
9.4.1. OVERVIEW
9.4.2. STRATEGIC MOVES
9.4.3. SCOT ANALYSIS
9.5. SHIONOGI & CO., LTD.
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC MOVES
9.5.4. SCOT ANALYSIS
9.6. ALLERGAN PLC
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. STRATEGIC MOVES
9.6.4. SCOT ANALYSIS
9.7. NEKTAR THERAPEUTICS
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC MOVES
9.7.4. SCOT ANALYSIS
9.8. PURDUE PHARMA L.P.
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. STRATEGIC MOVES
9.8.4. SCOT ANALYSIS
9.9. S.L.A. PHARMA AG
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. SCOT ANALYSIS
9.10. MUNDIPHARMA INTERNATIONAL LIMITED
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC MOVES
9.10.4. SCOT ANALYSIS
9.11. ONO PHARMACEUTICAL CO., LTD.
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. STRATEGIC MOVES
9.11.4. SCOT ANALYSIS
9.12. TAKEDA PHARMACEUTICAL COMPANY LIMITED
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. STRATEGIC MOVES
9.12.4. SCOT ANALYSIS
9.13. THERAVANCE BIOPHARMA INC
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. STRATEGIC MOVES
9.13.4. SCOT ANALYSIS
9.14. VALEANT PHARMACEUTICALS INTERNATIONAL
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. STRATEGIC MOVES
9.14.4. SCOT ANALYSIS
9.15. COSMO PHARMACEUTICALS SA
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. STRATEGIC MOVES
9.15.4. SCOT ANALYSIS
9.16. DAEWOONG PHARMACEUTICAL CO., LTD.
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. STRATEGIC MOVES
9.16.4. SCOT ANALYSIS
9.17. C.B. FLEET COMPANY, INC.
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. STRATEGIC MOVES
9.17.4. SCOT ANALYSIS
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. . TOP DOWN APPROACH
2.3. BOTTOM UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
4.5. MARKET DRIVERS
4.5.1. RISING USE OF OPIOID
4.5.2. INCREASING GERIATRIC POPULATION
4.5.3. EASY AVAILABILITY OF IMPROVED AND EFFECTIVE OIC DRUGS
4.6. RESTRAINTS
4.6.1. RESEARCH ON PAIN AND NEXT GENERATION ANALGESICS
4.6.2. SIDE EFFECTS OF OIC DRUGS
4.6.3. UNAWARENESS AND IGNORANCE AMONG PATIENTS
4.7. OPPORTUNITY
4.7.1. RISING DEMAND FOR OIC DRUGS FROM APAC MARKET
4.7.2. INCREASING USE OF OPIOIDS
4.8. CHALLENGES
4.8.1. LARGE NUMBER OF CONSIDERATIONS WHILE USING OPIOIDS
5. ASIA PACIFIC OIC DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)
5.1. OVERVIEW
5.1.1. METHYL NALTREXONE BROMIDE
5.1.2. LUBIPROSTONE
5.1.3. NALOXEGOL
5.2. PIPELINE DRUG ANALYSIS: PHASE 3: NALDEMEDINE (YEAR OF LAUNCH TO 2022 $ MILLION)
5.3. PIPELINE DRUG ANALYSIS: PHASE 2: ALVIMOPAN, DOLCANATIDE (QUALITATIVE INFORMATION)
5.4. PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH TO 2022 $ MILLION)
6. ASIA PACIFIC CIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
6.1. PRESCRIBED DRUGS
6.1.1. BRANDED
6.1.2. GENERIC
6.2. OVER THE COUNTER DRUGS
7. KEY ANALYTICS
7.1. PORTERS FIVE FORCE MODEL
7.1.1. INTENSITY OF COMPETITIVE RIVALRYOMPETITION AMONG THE
7.1.2. BARGAINING POWER OF SUPPLIERS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. THREAT OF SUBSTITUTE PRODUCTS
7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX
8. ASIA PACIFIC OIC DRUGS MARKET BY COUNTRIES 2017-2025 ($ MILLION)
8.1. CHINA
8.2. JAPAN
8.3. REST OF ASIA PACIFIC
9. COMPANY PROFILE
9.1. IRONWOOD PHARMACEUTICALS INC
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC MOVES
9.1.4. SCOT ANALYSIS
9.2. DAIICHI SANKYO CO LTD
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. STRATEGIC MOVES
9.2.4. SCOT ANALYSIS
9.3. PFIZER
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. STRATEGIC MOVES
9.3.4. SCOT ANALYSIS
9.4. PROGENICS PHARMACEUTICALS INC
9.4.1. OVERVIEW
9.4.2. STRATEGIC MOVES
9.4.3. SCOT ANALYSIS
9.5. SHIONOGI & CO., LTD.
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC MOVES
9.5.4. SCOT ANALYSIS
9.6. ALLERGAN PLC
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. STRATEGIC MOVES
9.6.4. SCOT ANALYSIS
9.7. NEKTAR THERAPEUTICS
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC MOVES
9.7.4. SCOT ANALYSIS
9.8. PURDUE PHARMA L.P.
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. STRATEGIC MOVES
9.8.4. SCOT ANALYSIS
9.9. S.L.A. PHARMA AG
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. SCOT ANALYSIS
9.10. MUNDIPHARMA INTERNATIONAL LIMITED
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC MOVES
9.10.4. SCOT ANALYSIS
9.11. ONO PHARMACEUTICAL CO., LTD.
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. STRATEGIC MOVES
9.11.4. SCOT ANALYSIS
9.12. TAKEDA PHARMACEUTICAL COMPANY LIMITED
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. STRATEGIC MOVES
9.12.4. SCOT ANALYSIS
9.13. THERAVANCE BIOPHARMA INC
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. STRATEGIC MOVES
9.13.4. SCOT ANALYSIS
9.14. VALEANT PHARMACEUTICALS INTERNATIONAL
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. STRATEGIC MOVES
9.14.4. SCOT ANALYSIS
9.15. COSMO PHARMACEUTICALS SA
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. STRATEGIC MOVES
9.15.4. SCOT ANALYSIS
9.16. DAEWOONG PHARMACEUTICAL CO., LTD.
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. STRATEGIC MOVES
9.16.4. SCOT ANALYSIS
9.17. C.B. FLEET COMPANY, INC.
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. STRATEGIC MOVES
9.17.4. SCOT ANALYSIS
LIST OF TABLES
TABLE 1 ASIA PACIFIC OIC DRUG MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 2 PHARMACOLOGICAL APPROACHES TO TREAT OPIOID INDUCED CONSTIPATION
TABLE 3 LAXATIVES USED FOR OPIOID INDUCED CONSTIPATION
TABLE 4 SIDE EFFECTS OF USING LAXATIVES
TABLE 5 PATIENTS UNFIT FOR INTAKE OF OPIOIDS
TABLE 6 ASIA PACIFIC OIC DRUG MARKET BY DRUG TYPE, 2017-2025 ($ MILLION)
TABLE 7 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 8 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 9 PRODUCT PROFILE (NALOXEGOL)
TABLE 10 PIPELINE PRODUCT PROFILE (NALDEMEDINE)
TABLE 11 PIPELINE PRODUCT PROFILE (ALVIMOPAN, DOLCANATIDE)
TABLE 12 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)
TABLE 13 ASIA PACIFIC OIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 14 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 15 ASIA PACIFIC PRESCRIBED OIC DRUGS MARKET 2017-2025($ MILLION)
TABLE 16 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 17 PRODUCT PROFILE (METAMUCIL)
TABLE 18 PRODUCT PROFILE (BISACODYL)
TABLE 19 ASIA PACIFIC OIC DRUG MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 1 ASIA PACIFIC OIC DRUG MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 2 PHARMACOLOGICAL APPROACHES TO TREAT OPIOID INDUCED CONSTIPATION
TABLE 3 LAXATIVES USED FOR OPIOID INDUCED CONSTIPATION
TABLE 4 SIDE EFFECTS OF USING LAXATIVES
TABLE 5 PATIENTS UNFIT FOR INTAKE OF OPIOIDS
TABLE 6 ASIA PACIFIC OIC DRUG MARKET BY DRUG TYPE, 2017-2025 ($ MILLION)
TABLE 7 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 8 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 9 PRODUCT PROFILE (NALOXEGOL)
TABLE 10 PIPELINE PRODUCT PROFILE (NALDEMEDINE)
TABLE 11 PIPELINE PRODUCT PROFILE (ALVIMOPAN, DOLCANATIDE)
TABLE 12 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)
TABLE 13 ASIA PACIFIC OIC DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 14 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 15 ASIA PACIFIC PRESCRIBED OIC DRUGS MARKET 2017-2025($ MILLION)
TABLE 16 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 17 PRODUCT PROFILE (METAMUCIL)
TABLE 18 PRODUCT PROFILE (BISACODYL)
TABLE 19 ASIA PACIFIC OIC DRUG MARKET BY COUNTRIES 2017-2025 ($ MILLION)
LIST OF FIGURES
FIGURE 1 ASIA PACIFIC OIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 2 ASIA PACIFIC OIC DRUG MARKET BY DRUG TYPE 2016 AND 2025 (%)
FIGURE 3 ASIA PACIFIC OIC DRUG MARKET BY PRESCRIPTION TYPE 2016 (%)
FIGURE 4 INCREASING NUMBER OF OPIOID PRESCRIPTION ($ MILLION)
FIGURE 5 REASONS FOR THE GROWTH OF OPIOID MARKET.
FIGURE 6 COMMON SIDE EFFECTS OF MOVANTIK
FIGURE 7 MAJOR USAGE OF OPIOIDS
FIGURE 8 CONSIDERATIONS TAKEN WHILE THE OPIOID USAGE
FIGURE 9 ASIA PACIFIC METHYL NALTREXONE BROMIDE OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 10 ASIA PACIFIC LUBIPROSTONE OIC DRUG MARKET 2017-2025 ($MILLION)
FIGURE 11 ASIA PACIFIC NALOXEGOL OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 12 ASIA PACIFIC PRESCRIBED OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 13 ASIA PACIFIC PRESCRIBED BRANDED OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 14 ASIA PACIFIC PRESCRIBED GENERIC OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 15 ASIA PACIFIC OVER THE COUNTER OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 16 ASIA PACIFIC OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 17 CHINA OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 18 PHARMACEUTICALS MARKET SALES ACROSS THE GLOBE (%)
FIGURE 19 JAPAN OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 20 REST OF APAC OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 1 ASIA PACIFIC OIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 2 ASIA PACIFIC OIC DRUG MARKET BY DRUG TYPE 2016 AND 2025 (%)
FIGURE 3 ASIA PACIFIC OIC DRUG MARKET BY PRESCRIPTION TYPE 2016 (%)
FIGURE 4 INCREASING NUMBER OF OPIOID PRESCRIPTION ($ MILLION)
FIGURE 5 REASONS FOR THE GROWTH OF OPIOID MARKET.
FIGURE 6 COMMON SIDE EFFECTS OF MOVANTIK
FIGURE 7 MAJOR USAGE OF OPIOIDS
FIGURE 8 CONSIDERATIONS TAKEN WHILE THE OPIOID USAGE
FIGURE 9 ASIA PACIFIC METHYL NALTREXONE BROMIDE OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 10 ASIA PACIFIC LUBIPROSTONE OIC DRUG MARKET 2017-2025 ($MILLION)
FIGURE 11 ASIA PACIFIC NALOXEGOL OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 12 ASIA PACIFIC PRESCRIBED OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 13 ASIA PACIFIC PRESCRIBED BRANDED OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 14 ASIA PACIFIC PRESCRIBED GENERIC OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 15 ASIA PACIFIC OVER THE COUNTER OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 16 ASIA PACIFIC OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 17 CHINA OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 18 PHARMACEUTICALS MARKET SALES ACROSS THE GLOBE (%)
FIGURE 19 JAPAN OIC DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 20 REST OF APAC OIC DRUG MARKET 2017-2025 ($ MILLION)
